• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

莱斯特咳嗽问卷的验证和难治性或不明原因慢性咳嗽的临床重要变化阈值。

Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough.

机构信息

Merck & Co., Inc., Rahway, NJ, USA.

Evidera, Seattle, WA, USA.

出版信息

Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221099737. doi: 10.1177/17534666221099737.

DOI:10.1177/17534666221099737
PMID:35614875
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9149626/
Abstract

INTRODUCTION

The Leicester Cough Questionnaire (LCQ), a cough-specific quality-of-life measure, evaluates the impact of cough across physical, psychological, and social domains in patients with chronic cough (CC). This study assessed the psychometric properties of the LCQ.

METHODS

Data from a phase IIb, randomized controlled trial of the P2X3-receptor antagonist gefapixant were analyzed (NCT02612610). Subjective [Cough Severity Diary, cough severity visual analogue scale, and patient global impression of change (PGIC)] and objective (awake and 24-h cough frequency) data were used to validate the LCQ for use in patients with refractory or unexplained CC (RCC and UCC, respectively). Psychometric analyses included confirmatory factor analyses, internal consistency and test-retest reliability, validity, responsiveness, and estimated within-patient thresholds for clinically meaningful change.

RESULTS

Model-fit values for the proposed three-factor LCQ domains and most individual items were acceptable. Analyses suggest that a mean improvement ranging from 1.3 to 2.3 points for the LCQ total and ⩾0.8, ⩾0.9, and ⩾0.8 points for physical, psychological, and social domain scores, respectively, had the best sensitivity and/or specificity for predicting patient ratings of improvement on the PGIC.

CONCLUSIONS

The LCQ is a valid and reliable measure to evaluate cough-specific quality of life and is a fit-for-purpose measure for use in patients with RCC or UCC. Although a single threshold for defining clinically meaningful change depends on the context of use, the results can help guide both treatment decisions and drug development. Therefore, clinicians may consider a ⩾1.3-point increase in the LCQ total score as clinically meaningful.

摘要

简介

莱斯特咳嗽问卷(LCQ)是一种咳嗽特异性生活质量量表,评估了慢性咳嗽(CC)患者咳嗽对身体、心理和社会领域的影响。本研究评估了 LCQ 的心理测量特性。

方法

对 P2X3 受体拮抗剂 gefapixant 的 IIb 期随机对照试验的数据进行了分析(NCT02612610)。使用主观[咳嗽严重程度日记、咳嗽严重程度视觉模拟量表和患者整体印象变化(PGIC)]和客观(清醒和 24 小时咳嗽频率)数据来验证 LCQ 在难治性或不明原因 CC(RCC 和 UCC)患者中的适用性。心理测量分析包括验证性因子分析、内部一致性和重测信度、有效性、反应性以及估计患者个体临床有意义变化的阈值。

结果

提出的三个 LCQ 领域和大多数单个项目的模型拟合值是可以接受的。分析表明,LCQ 总分的平均改善范围为 1.3 至 2.3 点,身体、心理和社会领域的得分分别为 0.8、0.9 和 0.8 点以上,对预测患者对 PGIC 的改善评分具有最佳的敏感性和/或特异性。

结论

LCQ 是一种有效的、可靠的评估咳嗽特异性生活质量的工具,适用于 RCC 或 UCC 患者。虽然定义临床有意义变化的单一阈值取决于使用的背景,但结果可以帮助指导治疗决策和药物开发。因此,临床医生可以考虑将 LCQ 总分增加 1.3 点作为临床有意义的变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afd3/9149626/596514852e3d/10.1177_17534666221099737-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afd3/9149626/acf0319a3047/10.1177_17534666221099737-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afd3/9149626/596514852e3d/10.1177_17534666221099737-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afd3/9149626/acf0319a3047/10.1177_17534666221099737-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afd3/9149626/596514852e3d/10.1177_17534666221099737-fig2.jpg

相似文献

1
Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough.莱斯特咳嗽问卷的验证和难治性或不明原因慢性咳嗽的临床重要变化阈值。
Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221099737. doi: 10.1177/17534666221099737.
2
Validation of a visual analog scale for assessing cough severity in patients with chronic cough.验证一种视觉模拟评分尺用于评估慢性咳嗽患者的咳嗽严重度。
Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211049743. doi: 10.1177/17534666211049743.
3
Quantitative measurement properties and score interpretation of the Cough Severity Diary in patients with chronic cough.慢性咳嗽患者咳嗽严重程度日记的定量测量特性和评分解读。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620915155. doi: 10.1177/1753466620915155.
4
Content validity of the Leicester Cough Questionnaire in adults with refractory or unexplained chronic cough: a qualitative interview study.莱斯特咳嗽问卷在难治性或不明原因的慢性咳嗽成人中的内容效度:一项定性访谈研究。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241274261. doi: 10.1177/17534666241274261.
5
Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups.吉法替尼改善慢性咳嗽的客观和主观指标:预先设定亚组的 3 期疗效汇总分析。
Lung. 2022 Aug;200(4):423-429. doi: 10.1007/s00408-022-00553-y. Epub 2022 Jul 27.
6
Validity and reliability of the Swedish version of the Leicester Cough Questionnaire in unexplained chronic cough.《莱斯特咳嗽问卷》瑞典语版在不明原因慢性咳嗽中的有效性和可靠性。
Respir Med. 2024 Apr;224:107582. doi: 10.1016/j.rmed.2024.107582. Epub 2024 Feb 28.
7
Clinical cough IV:what is the minimal important difference for the Leicester Cough Questionnaire?临床咳嗽IV:莱斯特咳嗽问卷的最小重要差异是多少?
Handb Exp Pharmacol. 2009(187):311-20. doi: 10.1007/978-3-540-79842-2_16.
8
Development of an Italian version of the Leicester cough questionnaire and its relationship with other symptom-specific measures for patients with chronic cough.莱斯特咳嗽问卷意大利语版本的开发及其与慢性咳嗽患者其他特定症状测量方法的关系。
Respir Med. 2024 Jun;227:107642. doi: 10.1016/j.rmed.2024.107642. Epub 2024 Apr 24.
9
Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant.参与 P2X3 受体拮抗剂 Gefapixant 二期临床试验的难治性或不明原因慢性咳嗽患者的特征。
Lung. 2021 Apr;199(2):121-129. doi: 10.1007/s00408-021-00437-7. Epub 2021 Apr 7.
10
Cough desensitization treatment for patients with refractory chronic cough: results of a second pilot randomized control trial.咳嗽脱敏治疗难治性慢性咳嗽患者:第二项随机对照试验的结果。
BMC Pulm Med. 2023 Apr 28;23(1):148. doi: 10.1186/s12890-023-02423-6.

引用本文的文献

1
Dupilumab reduces patient-reported cough and improves quality of life in patients with severe eosinophilic asthma with or without chronic rhinosinusitis with nasal polyps: a real-life prospective study.度普利尤单抗可减轻患者报告的咳嗽症状,并改善伴有或不伴有鼻息肉的慢性鼻-鼻窦炎的重度嗜酸性粒细胞性哮喘患者的生活质量:一项真实世界前瞻性研究。
Drugs Context. 2025 Aug 26;14. doi: 10.7573/dic.2025-6-3. eCollection 2025.
2
Efficacy and safety of flupentixol-melitracen in patients with refractory chronic cough: a randomised, double-blinded, placebo-controlled clinical trial.氟哌噻吨美利曲辛治疗难治性慢性咳嗽患者的疗效与安全性:一项随机、双盲、安慰剂对照临床试验
EClinicalMedicine. 2025 Aug 4;86:103367. doi: 10.1016/j.eclinm.2025.103367. eCollection 2025 Aug.
3

本文引用的文献

1
Quantitative measurement properties and score interpretation of the Cough Severity Diary in patients with chronic cough.慢性咳嗽患者咳嗽严重程度日记的定量测量特性和评分解读。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620915155. doi: 10.1177/1753466620915155.
2
Prevalence and incidence of, and risk factors for chronic cough in the adult population: the Rotterdam Study.成年人群慢性咳嗽的患病率、发病率及危险因素:鹿特丹研究
ERJ Open Res. 2020 Apr 19;6(2). doi: 10.1183/23120541.00300-2019. eCollection 2020 Apr.
3
Upper Airway Cough Syndrome in Pathogenesis of Chronic Cough.
Effectiveness of virtual, group cough modulation therapy for chronic refractory cough.虚拟小组咳嗽调节疗法对慢性难治性咳嗽的疗效
ERJ Open Res. 2025 Jul 14;11(4). doi: 10.1183/23120541.01151-2024. eCollection 2025 Jul.
4
Prevalence and burden of possible refractory chronic cough in four European countries.四个欧洲国家中可能难治性慢性咳嗽的患病率和负担
ERJ Open Res. 2025 Jul 14;11(4). doi: 10.1183/23120541.00888-2024. eCollection 2025 Jul.
5
Psychometric validation of the severity of chronic cough diary, leicester cough questionnaire, and a cough severity visual analogue scale in patients with refractory chronic cough.慢性咳嗽日记严重程度、莱斯特咳嗽问卷及咳嗽严重程度视觉模拟量表在难治性慢性咳嗽患者中的心理测量学验证
J Patient Rep Outcomes. 2025 Jun 11;9(1):65. doi: 10.1186/s41687-025-00888-z.
6
A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial.一种用于特发性肺纤维化的生成式人工智能发现的TNIK抑制剂:一项随机2a期试验。
Nat Med. 2025 Jun 3. doi: 10.1038/s41591-025-03743-2.
7
Effectiveness of ensitrelvir for cough caused by COVID-19 Omicron variant in patients with asthma.恩西他韦对哮喘患者中由新冠病毒奥密克戎变异株引起的咳嗽的疗效。
Microbiol Spectr. 2025 Apr 15;13(5):e0340724. doi: 10.1128/spectrum.03407-24.
8
Interpretation of Change in Novel Digital Measures: A Statistical Review and Tutorial.新型数字测量变化的解读:统计回顾与教程
Digit Biomark. 2025 Feb 3;9(1):52-66. doi: 10.1159/000543899. eCollection 2025 Jan-Dec.
9
Changes in quality of life of early-stage lung cancer patients undergoing sublobar resection: a systematic review.接受亚肺叶切除的早期肺癌患者生活质量的变化:一项系统评价
Front Surg. 2025 Feb 28;12:1542036. doi: 10.3389/fsurg.2025.1542036. eCollection 2025.
10
Chronic Cough Patient Perspective: questionnaire validation and symptom impact.慢性咳嗽患者视角:问卷验证与症状影响
ERJ Open Res. 2025 Jan 13;11(1). doi: 10.1183/23120541.00221-2024. eCollection 2025 Jan.
上气道咳嗽综合征在慢性咳嗽发病机制中的作用。
Physiol Res. 2020 Mar 27;69(Suppl 1):S35-S42. doi: 10.33549/physiolres.934400.
4
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.Gefapixant,一种 P2X3 受体拮抗剂,用于治疗难治性或原因不明的慢性咳嗽:一项随机、双盲、对照、平行分组、2b 期试验。
Lancet Respir Med. 2020 Aug;8(8):775-785. doi: 10.1016/S2213-2600(19)30471-0. Epub 2020 Feb 25.
5
ERS guidelines on the diagnosis and treatment of chronic cough in adults and children.ERS 指南:成人和儿童慢性咳嗽的诊断与治疗。
Eur Respir J. 2020 Jan 2;55(1). doi: 10.1183/13993003.01136-2019. Print 2020 Jan.
6
Validation of the Mandarin Chinese version of the Leicester Cough Questionnaire in non-small cell lung cancer patients after surgery.验证中文版莱斯特咳嗽问卷在非小细胞肺癌患者手术后的有效性。
Thorac Cancer. 2018 Apr;9(4):486-490. doi: 10.1111/1759-7714.12602. Epub 2018 Feb 27.
7
Classification of Cough as a Symptom in Adults and Management Algorithms: CHEST Guideline and Expert Panel Report.咳嗽在成人中的症状分类和管理算法:CHEST 指南和专家小组报告。
Chest. 2018 Jan;153(1):196-209. doi: 10.1016/j.chest.2017.10.016. Epub 2017 Nov 10.
8
The psychometric properties of the Leicester Cough Questionnaire and Respiratory Symptoms in CF tool in cystic fibrosis: A preliminary study.莱斯特咳嗽问卷和囊性纤维化患者呼吸症状评估工具在囊性纤维化中的心理测量特性:一项初步研究。
J Cyst Fibros. 2017 May;16(3):425-432. doi: 10.1016/j.jcf.2016.11.011. Epub 2016 Dec 14.
9
Validation of the Polish Version of the Chronic Cough Quality of Life Questionnaire (Leicester Cough Questionnaire).验证波兰版慢性咳嗽生活质量问卷(莱斯特咳嗽问卷)。
Adv Clin Exp Med. 2016 Jul-Aug;25(4):649-53. doi: 10.17219/acem/59512.
10
A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research.可靠性研究中组内相关系数选择与报告指南
J Chiropr Med. 2016 Jun;15(2):155-63. doi: 10.1016/j.jcm.2016.02.012. Epub 2016 Mar 31.